Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ILA-HP2F6 | Human | PE-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (Site-specific conjugation) | ![]() |
||
ILA-HF255 | Human | FITC-Labeled Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
ILA-M5253 | Mouse | Mouse IL-15 R alpha / CD215 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ILA-H82F4 | Human | Biotinylated Human IL-15 R alpha / CD215 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
ILA-H5253 | Human | Human IL-15 R alpha / CD215 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Immobilized Human IL-15, Tag Free (Cat. No. IL5-H4117) at 5 μg/mL (100 μL/well) can bind Mouse IL-15 R alpha, Fc Tag (Cat. No. ILA-M5253) with a linear range of 0.6-10 ng/mL (QC tested).
The purity of FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) is more than 85% and the molecular weight of this protein is around 115-140 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
PD-L1 t-haNK cell therapy/Inbakicept/Aldoxorubicin Hydrochloride(Immunitybio) | Phase 2 Clinical | Immunitybio Inc | Pancreatic Neoplasms | Details | |
SHR-1501 | SHR-1501 | Phase 1 Clinical | Neoplasms | Details | |
SO-C101 | RLI-15; SO-C101; CYP-0150; SOT-101 | Phase 1 Clinical | Sotio | Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Squamous Cell; Thymus Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Anus Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Biliary Tract Neoplasms | Details |
NKTR-255 | NKTR-255 | Phase 2 Clinical | Nektar Therapeutics | Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Multiple Myeloma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Uterine Cervical Neoplasms | Details |
Recombinant human interleukin 15(Beijing Kawin) | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | Solid tumours | Details | |
Inbakicept | N-803; ALT-803 | Phase 3 Clinical | Nantkwest Inc, Altor Bioscience Corporation | Multiple Myeloma; Carcinoma, Hepatocellular; Bacterial Infections; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lung Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Peritoneal Neoplasms; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Microsatellite Instability; Solid tumours; Chordoma; Urinary Bladder Neoplasms; Colonic Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Coronavirus Disease 2019 (COVID-19); Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Hematologic Diseases; Ovarian Neoplasms | Details |
XmAb24306 | XmAb-24306; RG-6323; RO-7310729; XmAb-306 | Phase 1 Clinical | Genentech Inc, Xencor | Solid tumours | Details |
KD-033 | KD-033 | Phase 1 Clinical | Takeda Pharma | Solid tumours | Details |
OXS-3550 | GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE; OXS-3550-TriKE | Phase 2 Clinical | University Of Minnesota, Oxis Biotech | Myelodysplastic Syndromes; Mastocytosis, Systemic; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute | Details |
RTX-240 | RTX-240 | Phase 2 Clinical | Rubius Therapeutics | Leukemia, Promyelocytic, Acute | Details |
Heterodimeric interleukin 15(Novartis Pharma) | NIZ-985 | Phase 1 Clinical | Novartis Pharma Ag | Solid tumours; Lymphoma; Melanoma | Details |
PF-07209960 | PF-07209960 | Phase 1 Clinical | Pfizer Inc | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
QL-415 | QL-415 | Phase 1 Clinical | Neoplasms | Details | |
BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Solid tumours; Communicable Diseases; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.